医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

QUAN: New Caregiver Robots Poised to Change Elderly Lives

2012年10月04日 PM06:00
このエントリーをはてなブックマークに追加


 

HOUSTON

As the world’s population ages, Quantum International Corp. (OTCBB: QUAN) is exploring new innovations capable of helping the elderly and chronically ill lead more independent and productive lives. Exciting new robotic assistants for caregivers could soon revolutionize home care for the aged and infirm.

In Japan, two new robots developed by ROBOHELPER are making it easier than ever before to care for elders at home. The ROBOHELPER SASUKE helps caregivers lift a person into and out of bed using a sling and servo motors. Another device, ROBOHELPER LOVE, is an automatic bodily waste disposal unit aimed at making bedpans a thing of the past.

ROBOHELPER LOVE’s cup wraps around the patient’s waist, fitted with sensors that automatically detect the presence of fluid and/or stool. The waste is then suctioned away into a holding tank, followed by a cleansing wash using room temperature water.

Personal assistance robots may represent a major breakthrough in home care as the global population of seniors grows rapidly. According to the U.S. Census Bureau, the number of elderly people in the world will exceed the number of children within a decade, placing greater demands on a shrinking number of young caregivers and taxing social insurance programs.

QUAN believes that personal care robots hold tremendous potential for reducing the stress on families and welfare institutions by automating many tasks currently provided by nurses and other caregivers. The company is currently investigating ways to capitalize on the demand for new robotics solutions to the pressing challenges faced by the healthcare industry in the 21st Century.

Quantum International Corp. is working to develop the next generation of robotics technology to compete in a booming global industry alongside Hansen Medical, Inc. (NASDAQ: HNSN), MAKO Surgical Corp. (NASDAQ: MAKO), Covidien (NYSE: COV) and Accuray Incorporated (NASDAQ: ARAY).

For more information on Quantum International’s robotics initiatives, please visit www.quantuminnovators.com/investors.html.

Follow us on Twitter at www.twitter.com/QuantumIntlCorp.

About Quantum International Corp.

Quantum International Corp. (OTCBB: QUAN) is a robotics innovation company working to commercialize the next generation of sophisticated, automated technology. The Company is positioning itself to develop, deliver and market the most cutting-edge innovations in robotics in order to leverage the worldwide demand for the precision, speed, and cost-effectiveness these technologies offer.

For more information about Quantum International Corp., please visit www.quantuminnovators.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

CONTACT

Quantum International Corp.
Robert Federowicz, 832-308-1260
President
and CEO
info@quantuminnovators.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表